Step Pharma
Duc has been an employee to Step Pharma since March 2020 acting as Chief Development Officer. He brings over twenty years of experience in drug discovery and drug development for big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics). Duc’s experience extends across many therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine. He has successfully delivered a number of projects into clinical development and on to registration. Duc is responsible for the drug development programs, providing pre-IND non-clinical, CMC and clinical leadership, implementing regulatory strategy, to ensure successful transition of lead candidates into clinical development.
Duc graduated from the French Grandes Ecoles d’ingénieurs ESPCI in Physics, Chemistry and Biology. Duc also holds a MSc degree in organic and bioorganic chemistry from Paris VI and is a registered Project Manager.
This person is not in any offices
Step Pharma
Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B cell populations.